Eupraxia Pharmaceuticals
EPRX • NASDAQ
Eupraxia Pharmaceuticals is a biotechnology company in the healthcare sector on NASDAQ, led by Bruce Cousins, with a market cap of $193.5M. As of Q3 2025, 39% of shares are held by 27 institutional investors, with Beutel, Goodman & Co Ltd. as the largest holder at -.
Chief Executive OfficerBruce Cousins
Overview
Overview of institutional ownership in EPRX as of Q3 2025 with a market cap of $193.5M
All Institutions
- Institutions
- 27
- Value Held
- $75.3M
- Shares Held
- 12.8M
- Avg Position
- $2.8M
- Median Position
- $268.9K
Hedge Funds
- Hedge Funds
- 5
- Value Held
- $21.9M
- Shares Held
- 3.7M
- Avg Position
- $4.4M
- Median Position
- $5.3M
Ownership Breakdown
Based on market cap of $193.5M as of Q3 2025. Institutional (non-HF) excludes hedge funds to avoid double counting.
Biggest Investors
Institutions with the largest positions in EPRX as of Q3 2025
| Institution | Position Value |
|---|---|
 Beutel, Goodman & Co Ltd. Long Only Manager | $23.9M 0.14% of portfolio |
 Vivo Capital, LLC Venture Capital | $8.0M 0.64% of portfolio |
 BALYASNY ASSET MANAGEMENT LLC Hedge Fund•Multi-Strategy | $8.0M 0.02% of portfolio |
S SCOTIA CAPITAL INC. Institution | $7.3M 0.03% of portfolio |
G GREAT POINT PARTNERS LLC Private Equity | $7.1M 3.12% of portfolio |
 Ally Bridge Group LLC Hedge Fund•Sector | $5.4M 4.52% of portfolio |
 Logos Global Management LP Hedge Fund•Long/Short | $5.3M 0.54% of portfolio |
R ROYAL BANK OF CANADA Institution | $2.5M 0.00% of portfolio |
V Velan Capital Investment Management LP Institution | $2.1M 1.95% of portfolio |
 Affinity Asset Advisors, LLC Hedge Fund•Long/Short | $1.8M 0.18% of portfolio |
Net Capital Flow
Institutional buying and selling activity for EPRX in Q3 2025
- Traded
- +$64.0M
- Buyers
- 22
- Sellers
- 4
- Total Bought
- +$64.2M
- Total Sold
- −$262.7K
- Avg Position
- $2.6M
Biggest Buyers
| Institution | Net Bought |
|---|---|
Beutel, Goodman & Co Ltd. Long Only Manager | +$23.9M +4.1M shares |
Vivo Capital, LLC Venture Capital | +$8.0M +1.4M shares |
BALYASNY ASSET MANAGEMENT LLC Hedge Fund•Multi-Strategy | +$8.0M +1.4M shares |
G GREAT POINT PARTNERS LLC Private Equity | +$7.1M +1.2M shares |
Ally Bridge Group LLC Hedge Fund•Sector | +$5.4M +915.0K shares |
Logos Global Management LP Hedge Fund•Long/Short | +$5.3M +900.0K shares |
V Velan Capital Investment Management LP Institution | +$2.1M +352.0K shares |
Affinity Asset Advisors, LLC Hedge Fund•Long/Short | +$1.8M +300.0K shares |
A Alyeska Investment Group, L.P. Hedge Fund•Multi-Strategy | +$1.5M +250.0K shares |
 UBS Group AG Institution | +$343.7K +58.3K shares |
Biggest Sellers
| Institution | Net Sold |
|---|---|
 CITADEL ADVISORS LLC Hedge Fund•Multi-Strategy | −$108.0K −18.2K shares |
S SCOTIA CAPITAL INC. Institution | −$80.1K −14.1K shares |
Q Quadrature Capital Ltd Institution | −$61.4K −10.7K shares |
 JPMORGAN CHASE & CO Institution | −$13.3K −2.3K shares |
Entry and Exit Activity
Institutions that initiated new positions or completely exited EPRX in Q3 2025
- New Positions
- 14
- New Value
- $63.4M
- Exited Positions
- 2
- Exited Value
- $169.3K
New Positions
| Institution | Position Value |
|---|---|
Beutel, Goodman & Co Ltd. Long Only Manager | $23.9M 4.1M shares |
Vivo Capital, LLC Venture Capital | $8.0M 1.4M shares |
BALYASNY ASSET MANAGEMENT LLC Hedge Fund•Multi-Strategy | $8.0M 1.4M shares |
G GREAT POINT PARTNERS LLC Private Equity | $7.1M 1.2M shares |
Ally Bridge Group LLC Hedge Fund•Sector | $5.4M 915.0K shares |
Logos Global Management LP Hedge Fund•Long/Short | $5.3M 900.0K shares |
V Velan Capital Investment Management LP Institution | $2.1M 352.0K shares |
Affinity Asset Advisors, LLC Hedge Fund•Long/Short | $1.8M 300.0K shares |
A Alyeska Investment Group, L.P. Hedge Fund•Multi-Strategy | $1.5M 250.0K shares |
 Guardian Partners Inc. RIA/Wealth | $147.4K 24.1K shares |
Exited Positions
| Institution | Previous Position |
|---|---|
CITADEL ADVISORS LLC Hedge Fund•Multi-Strategy | $108.0K 18.2K shares |
Q Quadrature Capital Ltd Institution | $61.4K 10.7K shares |
Options Activity
Institutions with the largest Call and Put options positions in EPRX as of Q3 2025
- Call Positions
- 0
- Call Value
- -
- Put Positions
- 0
- Put Value
- -
Call Positions
| Institution | Position Value |
|---|---|
| No call positions found | |
Put Positions
| Institution | Position Value |
|---|---|
| No put positions found | |
Most Committed Institutions
Institutions with EPRX as the highest % of their portfolio as of Q3 2025
| Institution | Portfolio Weight |
|---|---|
Ally Bridge Group LLC Hedge Fund•Sector | 4.52% $5.4M |
G GREAT POINT PARTNERS LLC Private Equity | 3.12% $7.1M |
V Velan Capital Investment Management LP Institution | 1.95% $2.1M |
Vivo Capital, LLC Venture Capital | 0.64% $8.0M |
Logos Global Management LP Hedge Fund•Long/Short | 0.54% $5.3M |
Affinity Asset Advisors, LLC Hedge Fund•Long/Short | 0.18% $1.8M |
Beutel, Goodman & Co Ltd. Long Only Manager | 0.14% $23.9M |
S SCOTIA CAPITAL INC. Institution | 0.03% $7.3M |
BALYASNY ASSET MANAGEMENT LLC Hedge Fund•Multi-Strategy | 0.02% $8.0M |
Guardian Partners Inc. RIA/Wealth | 0.01% $147.4K |
Hedge Fund Spotlight
Discover hedge funds investing in EPRX
Affinity Asset Advisors, LLC
Hedge Fund • Long/Short
Portfolio ManagerJonathan Bo-Shing Chu
- Portfolio Value
- $983.0M
- Positions
- 78
- Last Reported
- Q3 2025
Sector Allocation
Position in Eupraxia Pharmaceuticals
- Market Value
- $1.8M
- Shares Held
- 300.0K
- Portfolio Weight
- 0.18%
- Owned Since
- 2025-Q3
| Top Holding | Sector | Market Value | Weight |
|---|---|---|---|
Unknown Unknown | $66.7M | 6.78% | |
Biotechnology Healthcare | $64.8M | 6.59% | |
ETF ETF | $56.3M | 5.73% |
